USO 24326
A PHASE 1B, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF CHS-114 IN COMBINATION WITH TORIPALIMAB WITH OR WITHOUT OTHER TREATMENTS IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (CHS-114-102)
Disease Types: Gastrointestinal Cancer Research
Eligibility Requirements:
• Histologically or cytologically confirmed unresectable,
locally advanced or metastatic gastric or GEJ cancer
• Must be HER2-negative and MSS/pMMR
• Subject must have progressed during or after 1L therapy
that includes a platinum and fluoropyrimidine doublet with
or without anti-PD-1/PD-L1–directed therapy
• Subjects must provide a tumor tissue sample
• Subjects with prior exposure to an anti-CCR8 antibody are
excluded
• Subjects that have received ≥ 2 prior systemic anticancer
therapies for advanced or metastatic disease
For more information on this trial CLICK HERE .
Available at: